In the News

1923 News Items found
Dr. Zsofia Stadler smiles while leaning on a desk and wearing a stethoscope around her neck
A new MSK study has found that hereditary cancers are much more common than expected in patients over age 50, suggesting that everyone with cancer should be tested for these mutations.
Zaza Gelashvili, Miklos Lengyel, Philipp Niethammer, Yanan Ma
A team of MSK researchers solved a decades-old scientific puzzle and revealed that a critical inflammatory signaling pathway doesn’t just summon immune cells to the place where they’re needed — it also protects healthy cells from being damaged by the immune response.
The impact of a cancer diagnosis is felt not only by the patient, but by everyone who cares for them. In this issue, meet people whose stories reveal the power of compassion, collaboration, and showing up for one another when it matters most.
Young female scientist smiling in white coat and holding pipette.
Learn how MSK supported a young scientist after she was diagnosed with breast cancer.
Keisha Reader and Mortel Bartley stand together. Mortel has his arm around Keisha's shoulder.
Life changed dramatically for Keisha Reader when her brother, Mortel, was diagnosed with cancer, but there was no question she would do everything in her power to help him.
Mother holding her newborn baby.
Learn how MSK experts help navigate the special needs of people who have cancer during pregnancy
Tommy Ryan
When Tommy Ryan was strong enough to go home after 150 days at MSK Kids, his father wrote to personally thank the dozens of MSK staff members who had supported their family through the toughest time in their lives.
Learn more about MSK’s Herbal Oncology Program, the first such program in the nation, offering patients safe and effective herbal remedies to relieve the side effects of cancer treatment.
MSK research is revealing how cancer cells are active architects of their environment — remaking their cellular neighborhood in their own image — and these insights are helping to develop new ways to fight back.
Dr. Alison Schram
The FDA has approved lirafugratinib for patients with advanced cholangiocarcinoma that carries an FGFR2 fusion or rearrangement, giving them a new option for targeted therapy.